Minhang Xin
Overview
Explore the profile of Minhang Xin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuan B, Feng Y, Ma M, Duan W, Wu Y, Liu J, et al.
J Med Chem
. 2024 Nov;
67(22):20076-20099.
PMID: 39561981
Targeting the lysine residue of protein kinases to develop covalent inhibitors is an emerging hotspot. Herein, we have reported an approach to develop lysine-targeted covalent inhibitors of PI3Kδ by in...
2.
Wang F, Yang Z, Wu Y, Bai H, Xin M
Expert Opin Ther Pat
. 2024 Oct;
35(1):65-78.
PMID: 39451130
Introduction: Acute leukemia harboring rearrangement of the Mixed lineage leukemia (MLL) and/or mutation of the nucleophosmin is a type of poorly prognostic and highly malignant leukemia which is extremely difficult...
3.
Wang Y, Shi J, Xin M, Kahkoska A, Wang J, Gu Z
Nat Biomed Eng
. 2024 Jul;
8(11):1347-1365.
PMID: 38951139
By combining living cells with therapeutics, cell-drug conjugates can potentiate the functions of both components, particularly for applications in drug delivery and therapy. The conjugates can be designed to persist...
4.
Liu F, Xin M, Feng H, Zhang W, Liao Z, Sheng T, et al.
Sci Adv
. 2024 Mar;
10(13):eadk8264.
PMID: 38552011
Although CRISPR-mediated genome editing holds promise for cancer therapy, inadequate tumor targeting and potential off-target side effects hamper its outcomes. In this study, we present a strategy using cryo-shocked lung...
5.
Bai H, Yang Z, Lei H, Wu Y, Liu J, Yuan B, et al.
Eur J Med Chem
. 2024 Feb;
268:116226.
PMID: 38367493
To interfere the Menin-MLL interaction using small molecular inhibitors has been shown as new treatment of several special hematological malignancies. Herein, a series of Menin-MLL interaction inhibitors with pyrrolo[2,3-d]pyrimidine scaffold...
6.
Xi X, Zhao H, Mao Y, Xin M, Zhang S
Eur J Med Chem
. 2023 Oct;
261:115865.
PMID: 37839342
The EGFR mutation is a dominant mechanism of acquired resistance after the treatment of non-small cell lung cancer (NSCLC) with osimertinib in clinic. To date, there is no inhibitor approved...
7.
Bai H, Sun J, Lei H, Zhang S, Yuan B, Ma M, et al.
Drug Dev Res
. 2023 Sep;
84(8):1709-1723.
PMID: 37732677
The δ isoform of class I PI3K (PI3Kδ) has been shown as a promising target for the treatment of hematologic malignancies and immune diseases. Herein, a series of pyrido[3,2-d]pyrimidine derivatives...
8.
Gao L, Chuai H, Ma M, Zhang S, Zhang J, Li J, et al.
Bioorg Chem
. 2023 Sep;
140:106815.
PMID: 37672953
PI3Kδ inhibitors play an important role in the treatment of leukemia, lymphoma and autoimmune diseases. Herein, using our reported compounds as the lead compound, we designed and synthesized a series...
9.
Ma M, Feng Y, Zhang S, Duan W, Gao L, Yuan B, et al.
Future Med Chem
. 2023 Aug;
15(16):1491-1509.
PMID: 37565336
In our study compounds with pyrido[3,2-]pyrimidine and pyrido[3,4-]pyrimidine were designed, synthesized and evaluated for their biological activity against hematologic tumors. The biological activity of compounds was evaluated by ADP-Glo Luminescence...
10.
Lei H, Duan W, Zhang S, Feng Y, Ma M, Yuan B, et al.
Bioorg Chem
. 2023 May;
138:106594.
PMID: 37186998
The selective inhibition of PI3Kδ is a potential therapeutic strategy for the treatment of hematologic malignancies. Herein, we report a series of compounds bearing amino acid fragments as potent and...